Derivative exercise or conversion — not an open-market buy.
Traded Feb 26, 2026 · Filed Mar 2, 2026
The boss of Idexx Laboratories sold $1.88M of Idexx Laboratories shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,881,433
Shares × reported transaction price
24 days after results of Feb 2, 2026, 68 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $660.71 on Feb 26, 2026, 83% above its 52-week low and 14% below its high, after a 7% drop over the previous 30 trading days
52-week range $361.04 (Apr 8, 2025) to $766.68 (Nov 25, 2025), 74% of the way up, from 251 adjusted closes. 30 trading days earlier: $714.04 on Jan 13, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -5.8% | -0.5% | -5.3% |
| 30 days | -10.4% | -3.6% | -6.8% |
| 90 days | -10.8% | +11.5% | -22.3% |
| 180 days | -12.4% | +12.8% | -25.2% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
20K → 18K shares held−9% of their stake
Idexx Laboratories's Executive Vice President sold $1.12M of Idexx Laboratories shares. Nobody planned it ahead of time.